Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab added to lenalidomide and dexamethasone for poor responders with newly diagnosed multiple myeloma
ACTRN12617000958381Phase 2Withdrawn
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Increase in rate of at least partial response with addition of durvalumab. Planned start Aug 2017; status: withdrawn.
02
Drugs
durvalumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12617000958381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000958381.